Results 91 to 100 of about 361,159 (322)
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
New risk factors for post-surgical recurrent diabetic maculopathy in type 2 diabetes mellitus
Journal of Ophthalmology, 2019 Background: Some pathogenetic risk factors (platelet-derived growth factor (PDGF); tumor necrosis factor alpha (TNF?); and Endothelin-1 (ET1)) are involved in the development of diabetic maculopathy (DMP) in type 2 diabetes mellitus. We hypothesized that
S.Yu. Mogilevskyy +2 more
doaj +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Can Boost Immune Disruption
Cancer Management and Research, 2021 Asmaa M Zahran,1 Omnia El-Badawy,2 Lamiaa M Kamel,3 Amal Rayan,4 Khalid Rezk,5 Mona H Abdel-Rahim2 1Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt; 2Department of Medical Microbiology and Immunology ...
Zahran AM +5 more
doaj
Demonstratio Mathematica, 1999 A submanifold \(f: M^m \to \mathbb{R}^{m+d}\) is said to have pointwise \(k\)-planar normal section (P\(k\)-PNS) if, for each normal section \(\gamma\), the set \(\{\gamma'(0), \gamma''(0), {\cdots} , \gamma^{(k+1)}(0) \}\) is linearly dependent. Such an \(M\) is called proper (\(\text{PP}k\text{-PNS}\) if it is not P(\(k-1\))-PNS [\textit{B.-Y.
Arslan, Kadri +3 more
openaire +4 more sources
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Molecular Oncology, EarlyView.Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui +6 more
wiley +1 more source